



PRESS RELEASE

For Immediate Release

PsychoGenics Expands its *In Vivo* Testing Capabilities with the Addition of Novel Neurogenesis Techniques in Partnership with KineMed Inc.

TARRYTOWN, N.Y., February 14, 2011 - PsychoGenics Inc. today announced the establishment of an alliance with KineMed, Inc. to provide specialized neurogenesis services to complement PsychoGenics' *in vivo* testing capabilities.


KineMed has developed a novel analytical method to measure neuronal cell proliferation, differentiation and survival. This approach eliminates the need for the time consuming, labor intensive and often rate limiting step of histological analysis. In combination with PsychoGenics' extensive collection of animal models, it will enable an integrated assessment of the role of neurogenesis in psychiatric and neurodegenerative disorders. These new techniques for measuring the multiple stages of neurogenesis will complement and broaden PsychoGenics' *in vivo* and *in vitro* capabilities, and aid in the identification and analysis of CNS drug candidates for its numerous clients and partners.

"I am very much looking forward to working with PsychoGenics. The cutting-edge metrics of cellular dynamics in the living brain that we provide, should beautifully complement their extensive array of animal models and behavioral outcome measures. The resulting combination of contract research services and proprietary mass spectrometric technologies is extremely powerful" said Dr. Marc K. Hellerstein, M.D., Ph.D, KineMed co-founder and Chief of the Scientific Advisory Board and professor (DH Calloway Chair) at the University of California at Berkeley.

"We are excited to enter into this alliance with KineMed which will allow PsychoGenics to provide our clients and partners the ability to assess the effects of compounds on behavior and neurogenesis and correlate them with other neurochemical and molecular signals such as changes in transmitter and growth factor levels in the same animal," commented David Lowe, Ph.D., PsychoGenics' Chief Scientific Officer.

About PsychoGenics

PsychoGenics is a leader in preclinical behavioral neurobiology. The Company applies its behavioral expertise together with advances in robotics, computer vision, and informatics to provide innovative solutions for CNS drug discovery. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions, and not-for-profit research foundations to help discover treatments for such major neurological and psychiatric disorders as: ALS, anxiety, cognitive impairment, depression, Huntington's Disease, psychosis/schizophrenia, and Spinal Muscular Atrophy (SMA). The Company's in-house discovery efforts have focused on psychiatric indications. For more information about PsychoGenics please visit www.psychogenics.com.



About KineMed Inc.

KineMed, Inc. is a drug discovery and development company with a proprietary translational medicine approach that can help identify drug candidates at the preclinical stage and rapidly evaluate their clinical therapeutic activity and dose response in humans. KineMed has proprietary drug development programs and is engaged with pharmaceutical collaborators in therapeutic focus areas, where functional modulation of specific biological pathways that mediate disease can be demonstrated.

KineMed's technologies, including AquaTag™ and KineMarker™, these biomarkers expedite the drug development process and provide real-time insight into conditions including metabolic disorders, cancer, fibrotic diseases, inflammation, and neurodegeneration. For more information about KineMed, please visit: www.kinemed.com

For more information contact:

Paul McGonigle, Ph.D.

V.P., External Scientific Affairs

Ph: (914) 406-8000

paul.mcgonigle@psychogenics.com